Fundraising Fox
🦊/Companies
Sign in

Resalis Therapeutics

Turin, IT · 4 known investors

Find your way into Resalis Therapeutics

348 people in our graph share verified history with the Resalis Therapeutics team — schools, employers, funds. One of them is your warm intro.

Jennifer Scott Fonstadunlockedknows Riccardo Panella · together at Harvard Business School (overlapped)
×10knows the team · via Harvard Business School
knows the team · via Università degli Studi di Perugia

Resalis Therapeutics develops antisense oligonucleotide therapies targeting microRNA pathways for metabolic disorders. The company is advancing RES-010, a treatment candidate for obesity, fatty liver disease, and related metabolic disorders.

BiotechHealthtechLongevityMedical Devices

Founders & leadership

RPRiccardo Panella
Riccardo PanellainChief Scientific Officer & Co-FounderRiccardo Panella is an Associate Professor at the Center for RNA Medicine at Aalborg University's Copenhagen campus and Chief Scientific Officer and co-founder of Resalis Therapeutics, which develops antisense oligonucleotide therapies targeting microRNA pathways for metabolic disorders.
SKSakari Kauppinen
Sakari KauppineninChief Technology Officer & Co-Founder

Investors · 4

Claris VenturesTurin
Italian Angels for GrowthMilan
Sunstone CapitalreportedFrederiksberg

Also in the syndicate · 1

Sunstone Life Science Ventureslead

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries AJan 2024

    Sunstone Life Science Ventures (lead)

    Source ↗
  • Undisclosed amountSeed FinancingFeb 2023
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Resalis Therapeutics gets equity investment from Sanofi - European Biotechnology Magazineeuropean-biotechnology.com · Oct 2024Resalis Therapeutics Raises €10 Million Series A to Complete First Clinical Trial for RES-010 in Obesity - Global Wellness Summitglobalwellnesssummit.com · Jan 2024Resalis Therapeutics receives €10M to develop obesity and NAFLD treatmentlabiotech.eu · Feb 2023Resalis Therapeutics Raises €10M in Seed Financingfinsmes.com · Feb 2023

Frequently asked questions

What does Resalis Therapeutics do?
Resalis Therapeutics develops antisense oligonucleotide therapies targeting microRNA pathways for metabolic disorders. The company is advancing RES-010, a treatment candidate for obesity, fatty liver disease, and related metabolic disorders.
Who founded Resalis Therapeutics?
Resalis Therapeutics was founded by Riccardo Panella, Sakari Kauppinen.
Who are Resalis Therapeutics's investors?
Resalis Therapeutics's investors include Claris Ventures, Italian Angels for Growth, Sunstone Capital.
Where is Resalis Therapeutics headquartered?
Resalis Therapeutics is headquartered in Turin, IT.